ABVC
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
ABVC BioPharma, Inc. (ABVC) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (C-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | C+ (2.5) | C+ (2.5) | C- (1.9) | C+ (2.6) | C+ (2.6) | C (2.4) |
| 2026-11-10 | C+ (2.5) | C+ (2.5) | C (2.5) | C+ (2.7) | C+ (2.6) | C+ (2.6) |
| 2026-11-03 | C+ (2.5) | C+ (2.5) | C+ (2.5) | C (2.5) | C+ (2.7) | C+ (2.5) |
| 2026-10-27 | C+ (2.5) | C+ (2.5) | C (2.5) | C+ (2.5) | C+ (2.6) | C+ (2.5) |
| 2026-10-20 | C+ (2.5) | C+ (2.5) | C (2.5) | C- (1.9) | C+ (2.6) | C (2.4) |